Stayble Therapeutics AB (publ) (STABL.ST)
SEK 0.51
(2.0%)
SEK 0.51
(2.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 309.41 Thousand SEK | 101.08% |
| 2022 | - SEK | -103.59% |
| 2021 | - SEK | 20.26% |
| 2020 | - SEK | -119.57% |
| 2019 | - SEK | -12.32% |
| 2018 | -2676.00 SEK | -118.74% |
| 2017 | -2179.00 SEK | -135.55% |
| 2016 | -1.18 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.81 Million SEK | 32.43% |
| 2024 Q2 | -3.7 Million SEK | -1318.55% |
| 2023 FY | - SEK | 2.02% |
| 2023 Q3 | -6.81 Million SEK | -2.54% |
| 2023 Q1 | -3.74 Million SEK | 23.34% |
| 2023 Q2 | -6.64 Million SEK | -77.61% |
| 2023 Q4 | -6.57 Million SEK | 3.56% |
| 2022 FY | - SEK | -103.59% |
| 2022 Q3 | -5.78 Million SEK | 10.0% |
| 2022 Q2 | -6.42 Million SEK | 13.17% |
| 2022 Q1 | -7.4 Million SEK | -62.69% |
| 2022 Q4 | -4.88 Million SEK | 15.63% |
| 2021 Q1 | -2.03 Million SEK | -88.37% |
| 2021 FY | - SEK | 20.26% |
| 2021 Q3 | -3.01 Million SEK | -26.62% |
| 2021 Q2 | -2.38 Million SEK | -17.05% |
| 2021 Q4 | -4.55 Million SEK | -50.87% |
| 2020 Q1 | -5.04 Million SEK | -63.04% |
| 2020 Q2 | -6.32 Million SEK | -25.38% |
| 2020 Q4 | -1.08 Million SEK | 59.14% |
| 2020 FY | - SEK | -119.57% |
| 2020 Q3 | -2.64 Million SEK | 58.18% |
| 2019 Q2 | -1.21 Million SEK | 33.33% |
| 2019 Q1 | -1.82 Million SEK | -97.9% |
| 2019 Q4 | -3.09 Million SEK | -315.19% |
| 2019 FY | - SEK | -12.32% |
| 2019 Q3 | -745 Thousand SEK | 38.63% |
| 2018 Q4 | -920.1 Thousand SEK | 0.0% |
| 2018 FY | - SEK | -118.74% |
| 2017 FY | - SEK | -135.55% |
| 2016 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 100.084% |
| AcouSort AB (publ) | -16.7 Million SEK | 101.852% |
| Active Biotech AB (publ) | -43.88 Million SEK | 100.705% |
| Alzinova AB (publ) | 41.99 Thousand SEK | -636.715% |
| Amniotics AB (publ) | -27.14 Million SEK | 101.14% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 102.176% |
| BioArctic AB (publ) | 275.38 Million SEK | 99.888% |
| Camurus AB (publ) | 562.54 Million SEK | 99.945% |
| Cantargia AB (publ) | -284.31 Million SEK | 100.109% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 101.58% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 101.811% |
| Genovis AB (publ.) | 64.57 Million SEK | 99.521% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 100.269% |
| Mendus AB (publ) | -97.84 Million SEK | 100.316% |
| Kancera AB (publ) | -61.88 Million SEK | 100.5% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 101.155% |
| LIDDS AB (publ) | -39.67 Million SEK | 100.78% |
| Lipum AB (publ) | -37.11 Million SEK | 100.834% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 102.556% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 99.015% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | -15370.65% |
| NextCell Pharma AB | -40.98 Million SEK | 100.755% |
| OncoZenge AB (publ) | 7.26 Million SEK | 95.742% |
| Saniona AB (publ) | -69.69 Million SEK | 100.444% |
| Simris Alg AB (publ) | -22.36 Million SEK | 101.384% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 100.097% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 100.11% |
| Xintela AB (publ) | -53.47 Million SEK | 100.579% |
| Ziccum AB (publ) | -20.34 Million SEK | 101.521% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 100.836% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 100.182% |
| CombiGene AB (publ) | -35.33 Million SEK | 100.876% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 100.22% |
| Intervacc AB (publ) | -68.98 Million SEK | 100.449% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 100.13% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 114.876% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 102.304% |
| Corline Biomedical AB | -1.69 Million SEK | 118.298% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 100.179% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 100.565% |
| Aptahem AB (publ) | -10 Million SEK | 103.091% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 97.321% |
| Fluicell AB (publ) | -25.91 Million SEK | 101.194% |
| Biovica International AB (publ) | -119.5 Million SEK | 100.259% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 100.733% |
| Abliva AB (publ) | -93.6 Million SEK | 100.331% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 100.097% |
| 2cureX AB (publ) | -35.13 Million SEK | 100.881% |
| I-Tech AB | 30.34 Million SEK | 98.98% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 100.043% |
| Cyxone AB (publ) | -20.41 Million SEK | 101.516% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 100.302% |
| Biosergen AB | 228 Thousand SEK | -35.707% |
| Nanologica AB (publ) | -62.11 Million SEK | 100.498% |
| SynAct Pharma AB | -222.7 Million SEK | 100.139% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 100.705% |
| BioInvent International AB (publ) | -312.7 Million SEK | 100.099% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 100.134% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 103.511% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 100.285% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 102.698% |